CNXU

distress 3/10 · well-funded / low risk

$9.40+1%today-44% from 52w high

conexeu.comFounded 2022Reno, NVBiotechnology

Revenue

pre-revenue

Liquidity

$7M

Runway

—

Shares 1y

—

Price & events

-28.0% over 6M

CatalystRating changeDilutionFinancingdashed = today

+0.7%

-10.5%

-10.9%

—

-28.0%

All

Overview

Market Cap: $251.66M
Volume: 12.31K
52 Week Range: $8.88 – $16.85
Total Shares: 26.76M
Float Shares: 19.12M
% Held by Insiders: 40.98%
% Held by Institutions: 0.00%
RVOL: 0.12x

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 0

No catalyst news yet.

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 26,758,330 · 4 offerings/1y · 2 PIPEs

2026-06-16424B3offering
2026-06-098-Kprivate_placement
2026-05-158-Kprivate_placement
2026-05-15424B3offering
2026-05-15424B3offering
2026-05-11424B4offering
2026-05-11EFFECTshelf_effective

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

strong buy · target $20 (+113% upside) · 1 analysts

2026-06-22HC Wainwright & Co.Buy

Competitors

none identified